Edition:
India

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

68.68EUR
23 Jul 2018
Change (% chg)

€-0.78 (-1.12%)
Prev Close
€69.46
Open
€69.26
Day's High
€69.26
Day's Low
€68.64
Volume
30,300
Avg. Vol
1,352,190
52-wk High
€74.06
52-wk Low
€58.96

Chart for

About

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes... (more)

Overall

Beta: 0.56
Market Cap(Mil.): €39,028.29
Shares Outstanding(Mil.): 554.54
Dividend: 0.62
Yield (%): 0.88

Financials

Fresenius transfers inpatient rehabilitation business to Vamed unit

FRANKFURT, June 6 German healthcare group Fresenius said it was transferring its inpatient rehabilitation business from its private hospital operations to its Fresenius Vamed unit to better enable continued growth at the two businesses.

06 Jun 2018

Fresenius CEO defends canceled Akorn deal

FRANKFURT/BERLIN Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn , saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

UPDATE 1-Fresenius CEO defends cancelled Akorn deal

* Expects legal proceedings to conclude in 2019 (Adds details on expenses, comment on provision, analyst)

18 May 2018

Fresenius CEO defends cancelled Akorn deal

FRANKFURT/BERLIN, May 18 Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

18 May 2018

Fresenius Q1 net income slips 2 pct on strong euro

BERLIN, May 3 German healthcare group Fresenius SE posted a slight decline in quarterly profit on Thursday, hurt by a strong euro, and confirmed its full-year guidance.

03 May 2018

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

03 May 2018

UPDATE 2-Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

WILMINGTON, Del./NEW YORK, May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

02 May 2018

Fresenius alleges "blatant fraud" at abandoned target Akorn

WILMINGTON, Del., May 2 German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware's Court of Chancery.

02 May 2018

BRIEF-Fresenius says believes that Akorn lawsuit is without foundation

* AKORN, INC. SUES FRESENIUS FOR CONSUMMATION OF MERGER AGREEMENT AFTER ITS TERMINATION BY FRESENIUS

23 Apr 2018

Jilted Akorn sues Fresenius over deal termination

FRANKFURT U.S. generic drugmaker Akorn is taking former suitor Fresenius to court after the German healthcare group canceled their $4.75 billion takeover agreement.

23 Apr 2018

Earnings vs. Estimates